banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Kathy  McGraw

Kathy McGraw

Kathy McGraw

  

Bio

fiogf49gjkf0d

Dr. Kathy McGraw successfully defended her dissertation on June 20, 2013 and is pictured here with her committee. From left to right: Committee members Sheng Wei and P.K. Epling-Burnette; Major Professor Alan List; Kathy; external chair Benjamin Ebert from Harvard Medical School; committee member Gary Reuther. Dr. McGraw is now a Research Scientist in the lab of Dr. Alan List at Moffitt Cancer Center.

Dr. McGraw's publications while in the Program:

Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW.JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.Br J Haematol. 2013 Jan;160(2):177-87. doi:10.1111/bjh.12103.PMID:23157224

Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP Jr, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK.Naïve T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.Leukemia. 2012 Oct 17. doi: 10.1038/leu.2012.300. PMID: 23072779

Wei S, Chen X, McGraw KL, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu E, Sallman D, Wang H, Epling-Burnette P, Djeu J, Maciejewski J, Sekeres M, and List A. Lenalidomide Promotes p53 Degradation by Inhibiting MDM2 Auto-ubiquitination in Myelodysplastic Syndrome with Chromosome 5q Deletion. Oncogene. 2012 Apr 23. doi: 10.1038/onc.2012.139

Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol. 2012 Mar 5;5(1):4.

McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF.Erythropoietin receptor signaling is membrane raft dependent. PLoS One. 2012;7(4):e34477.

Jerez A, Sugimoto Y, Makishima H, Verma, A, Jankowska AM, Przychodzen B, Visconte V, Tiu, RV, O’Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kujima S, List A, Boultwood J, Mufti GJ, Maciejewski JP. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012 Jun 21;119(25):6109-17.

Caceres G, Robey R, Sokol L, McGraw K, Clark J, Lawrence N, Sebti S, Wiese M, List A. HG-829 is a potent non-competitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Research. Cancer Res. 2012 Jul 3.

Andres Jerez, Michael Clemente, Hideki Makishima, Hanna Koskela, Francis LeBlanc, Kwok Peng Ng, Thomas Olson, Bartlomiej Przychodzen, Manuel Afable, Ines Gomez-Segui, Kathryn Guinta, Elizabeth Durkin, Eric D Hsi, Kathy McGraw, Dan Zhang, Marcin W Wlodarski, Kimmo Porkka, Mikkael A Sekeres, Alan List, Satu Mustjoki, Thomas P Loughran, and Jaroslaw P Maciejewski. STAT3 mutations in clonal natural killer and cytotoxic T lymphocytes unify the pathogenesis of large granular lymphocyte leukemia. Blood. 2012.Oct 11;120(15):3048-57. doi: 10.1182/blood-2012-06-435297. Epub 2012 Aug 2.PMID: 22859607

Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu C, McGraw K, Clark JA, Sigua CA, Chen D, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature ein myelodysplastic syndromes. Br J Haematol, 2011 Apr;153(1):24-32.

Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leukemia Research. Jun 2010, 34:821-823.

Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. 2009. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. PNAS. PNAS Early Edition 1-6

Dr. McGraw's publications since graduation:

Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagström S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP Jr, Maciejewski JP. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013 Oct 3;122(14):2453-9. doi: 10.1182/blood-2013-04-494930. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 22;123(21):3364. PMID: 23926297

Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16127-32. doi: 10.1073/pnas.1311055110. Epub 2013 Sep 16. PMID: 24043769

McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014 Dec 3;9(12):e114249. doi: 10.1371/journal.pone.0114249. eCollection 2014. PMID: 25469886

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar 13;5:e291. PMID: 25768405

McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct 27 . PMID: 26416416

Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau MM, Steidl U, List AF, Evans T, Verma A, Wickrema A.Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes./em> Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6359-68. Epub 2015 Nov 2. PMID: 26578796